University Health Network, Princess Margaret Hospital

Summary

University Health Network, Princess Margaret Hospital is a medical facility located in TORONTO, Ontario. This center is recognized for care of Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Pancreatic Cancer and other specialties. University Health Network, Princess Margaret Hospital is involved with conducting 300 clinical trials across 413 conditions. There are 31 research doctors associated with this hospital, such as Amit Oza, MD, Lillian Siu, MD, Philippe Bedard, and Marcus Butler.

Top PIs

Clinical Trials running at University Health Network, Princess Margaret Hospital

Cancer

Skin Cancer

Prostate Cancer

Pancreatic Cancer

Bladder Cancer

Acute Myeloid Leukemia

Lung Cancer

Testicular cancer

Small Cell Lung Cancer

Brain Tumor

Continued Darolutamide Treatment

for Cancer

This trial continues darolutamide treatment for patients who were part of a previous study and are believed to benefit from it. Darolutamide helps by blocking hormones that can make cancer cells grow. Patients will keep taking the same dosage and visit their doctors regularly. Darolutamide has been shown to slow cancer spread and improve survival in patients with nonmetastatic castration-resistant prostate cancer.

Recruiting

2 awards

Phase 3

4 criteria

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Recruiting

2 awards

Phase 3

26 criteria

Immunotherapy + Chemotherapy

for Sarcoma

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.

Recruiting

2 awards

Phase 3

10 criteria